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A B S T R A C T
Purpose: In order to estimate and compare the long-term effectiveness of lamotrigine (LTG) versus
valproate (VPA) monotherapy in treatment of newly diagnosed idiopathic generalized epilepsies (IGE)
the following study was performed.
Methods: Medical records of 214 children and adolescents suffering from IGE were analyzed. 132 of
them were on VPA monotherapy, 82 on LTG. The majority of patients had juvenile myoclonic epilepsy –
98, the rest: juvenile absence epilepsy – 32, childhood absence epilepsy – 53 and epilepsy with a tonic–
clonic seizures on awakening – 12, others – 19. Mean age of the patients was 8.9 years (range 4–16
years). The mean time of treatment was 28 months, time of observation 40 months. In order to estimate
retention rates and factors predicting successful treatment with LTG and VPA we used Kapplan–Meyer
analysis and Gehan tests.
Results: Data analysis showed signiﬁcantly longer retention rates with VPA versus LTG treatment in
overall rates as well in all syndromes subgroups. After 12 months of therapy 69% stayed on LTG therapy
versus 89% on VPA, after 24 months 57% versus 83% respectively. VPA showed comparable efﬁcacy in all
IGE syndromes where LTG showed better efﬁcacy in childhood and juvenile absence epilepsy than in
juvenile myoclonic epilepsy. The shorter duration of treatment with LTG was due to lack of efﬁcacy.
Conclusions: Our results show the superiority of VPA versus LTG treatment in idiopathic generalized
epilepsy syndromes.
 2010 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Idiopathic generalized epilepsies (IGE) are genetically deter-
mined and affect otherwise normal people of both sexes and races.
They manifest with generalized tonic–clonic seizures, typical
absence seizures and myoclonic jerks alone or in varying
combinations and severity. In general IGE respond to treatment,
with approximately 80% becoming fully controlled 1. Monotherapy
is considered to be the goal in the ﬁrst line pharmacologic
management of epilepsy as it is effective, well tolerated and
associated with low costs, better patient compliance and higher
quality of life. Although conventional anti-epileptic drug (AED)
valproate and the modern AED lamotrigine are identiﬁed as
optimal ﬁrst line or second-line monotherapy for idiopathic
generalized epilepsies, effectiveness and course of treatment vary
between the patients and are still a matter of discussion.
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generalized tonic–clonic epilepsy according to NICE guidelines 2.
Valproate is a very effective anticonvulsant drug (AED) for IGE
however it carries some risks connected with it’s side effects
proﬁle. There is still limited evidence with head to head
comparision of this two agents in clinical settings 3. The goal of
present study was to estimate and compare the long-term
effectiveness of lamotrigine (LTG) versus valproate (VPA) mono-
therapy in treatment of idiopathic generalized epilepsies (IGE).
2. Materials and methods
Medical records of 214 children and adolescents suffering from
IGE (patients of Developmental Neurology Department and
Outpatient Clinic during 1999–2008) were analyzed. All of the
patients were newly diagnosed with IGE and previously not
treated. 132 of them were on VPA monotherapy, 82 on LTG. The
majority of patients had juvenile myoclonic epilepsy – 98, juvenile
absence epilepsy – 32, childhood absence epilepsy – 53 and
epilepsy with a tonic–clonic seizures on awakening – 12, others –
19 (included 4 patients presenting absences with eyelid myoclo-
nias, 5 with myoclonic absences and 10 who did not fulﬁll criteria
for ‘‘pure’’ childhood absence epilepsy (photosensitivity, early invier Ltd. All rights reserved.
Table 1
Group characteristics.
LTG VPA
Number of patients 82 132
Males/Females 27/55 62/70
Mean age of seizure onset 8.5 (4–16) 9.2 (4–16)
Mean weight (kg) 32,2 (17.2–101) 27.1 (18.5–72.2)
Types of epileptic seizures
Myoclonic 39 82
Absence 41 59
Tonic–clonic 25 32
Types of epilepsy syndrome
Juvenile myoclonic epilepsy (JME) 35 63
Childhood absence epilepsy (CAE) 21 32
Juvenile absence epilepsy (JAE) 15 17
Epilepsy with tonic–clonic
seizures on awakening
7 5
Others 4 15
Note: Some patients had more than one type of epileptic seizure.
Fig. 1. Retention rates lamotrigine versus valproate in idiopathic generalized
epilepsies.
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age of the patients was 8.9 years (range 4–16 years). The group
characteristics are presented in Table 1. The mean time of
treatment was 28 months, time of observation 40 months. Mean
doses of LTG were 8 mg/kg/day (range 5–13 mg/kg/day), for VPA
25 mg/kg/day (range 20–32 mg/kg/day). In order to estimate
retention rates and factors predicting successful treatment with
LTG and VPA we used Kapplan–Meyer analysis and Gehan tests.
3. Results
Data analysis showed signiﬁcantly longer retention rates with
VPA versus LTG treatment in overall rates as well in major
syndromes subgroups. After 12 months of therapy 69% of patients
stayed on LTG therapy versus 89% on VPA, after 24 months 57%
versus 83% respectively (Fig. 1). VPA showed comparable efﬁcacy in
all IGE syndromes, where LTG showed better efﬁcacy in childhood
and juvenile absence epilepsy than in juvenile myoclonic epilepsy
(Table 2). The shorter duration of treatment with LTG was due to
lack of efﬁcacy (Table 3). Therewere no differences inmental status
as well as severity of EEG changes in subgroups of patients who
continued or discontinued the treatment. Side effects were
important reasons for discontinuation of the therapy. 10 patients
receiving VPA ceased the treatment because of: weight gain, hair
loss, diarrhoea, stomach pain. 2 patients treated with LTG
discontinued further treatment due to rash.Table 2
Mean duration (months) of treatment for all patients with IGE and according to major t
absence epilepsy).
All patients JME
Number of patients Mean Range Number of patients
VPA 132 34.6 1–69 63
LTG 82 19.2 1–57 35
Table 3
Reason of discontinuation of lamotrigine and valproate in patients with idiopathic g
discontinued the drug.
Discontinued (number of patients) (%) Mean duration of treatm
Valproate 28/19.7 12.3
Lamotrigine 47/57.3 9.74. Discussion
Our study is one of the few comparing the retention rates of
new AED–LTG with classical AED–VPA, that has well established
efﬁcacy in this type of epilepsy. This is an observational study
performed in a single centre, thus there was no risk of
methodological differences which could be present in studies
where patients from several referral centers are included. It seems
to be important, that all the patients were not previously treated
with any AED.
The sample group is relatively large and we hope that the
results reﬂect the reality in clinical practice. The VPA and LTG
groups, as well as the subgroups of different epileptic syndromes
(JME, CAE, JAE) were similar according to age. There were
signiﬁcantly more females in LTG group. LTG was prescribed
especially to girls because of potential lack of adverse events
crucial for female-teenagers such as hyperandrogenism and
potential teratogenity 4–8 aswell for patientswhowere overweight
or had a tendency to gain on weight.
Long-term tolerability of AEDs in children is important, because
the adverse event proﬁle of the drug is often a major determinant
in the choice of therapy.
However, in our study better tolerability and relatively small
rate of side effects did not correlate with longer period of therapy.
Principal reason of earlier discontinuation of therapy in LTG group
was referred to lower efﬁcacy in comparison to VPA group.ypes of epilepsy syndromes (JME – juvenile myoclonic epilepsy or CAE – childhood
CAE
Mean Range Number of patients Mean Range
38.1 1–69 32 39.8 1–69
8.4 1–42 21 26.1 1–57
eneralized epilepsy and mean duration (months) of treatment in patients who
ent Lack of efﬁcacy Adverse effects Others Lost to follow up
14 10 2 2
39 2 3 3
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maintenance of seizure control. At the same time, we did not ﬁnd
the support to previous statements that lamotrigine could serve as
alternative treatment to valproate in forms of IGE 9–14.
Comparability is never perfect in a non-randomized study, but it
is unlikely that the differences in outcomes could be a result of using
inappropriate doses of some AED. The doses of the AED surveyed in
the study werewithin the recommended target levels 15. This study
was not a controlled trial and in these patients drugs were normally
adjusted depending on the efﬁcacy and the tolerability.
The duration of treatment with AED (retention rate) strongly
associates with two major factors – the efﬁcacy and the adverse
events. In many cases a proﬁt of successful treatment of epilepsy—
which means reduction or even elimination of seizures—over-
weighs the expense of adverse effects. For this reason, further
comparable long-term studies should be performed in order to
assess the signiﬁcance of side effects in particular age groups of
patients with marked improvement on valproate therapy.
Discontinuations of AED owing to adverse effects occurred
quite early in the course of treatment, usually within the ﬁrst six
months. In our study adverse effects were the reason of
discontinuation in 5.6% of patients (7.6% on VPA and 2.4% on
LTG). It shows, that LTGwas better tolerated but the lack of efﬁcacy
was crucial for the smaller retention rate with this drug. 47.6% of
patients on LTG discontinued the study due to lack of efﬁcacy
versus 10.6% on VPA therapy.
Data in the literature suggests that the primary reason for fail
the newly introduced anti-epileptic treatment is a lack of efﬁcacy
rather than adverse effects. Proper decision of neurologist is
essential as inadequate response to initial treatment is believed to
be a poor prognostic factor in further course of epilepsy 16.
Especially for children and adolescents it is extremely impor-
tant to start the therapy with the drug, that provides the patient a
greater chance for being seizure free (between others, also from
the social and psychological point of view). It is important to
mention that in long-term therapy with VPA it is possible to
maintain the therapeutic effect on reduced dosewith the beneﬁt of
reduced adverse effects including teratogenicity 17.
5. Conclusions
In conclusion, our study suggests that there are clinically
signiﬁcant differences between lamortrigine and valproate interms of efﬁcacy in idiopathic generalized epilepsies. Furthermore,
our study supports the value of retention rate studies in assessing
outcome of the drugs in clinical practice.
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